MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

The latest financial statement is for the quarter ending 2025-12-31.

Cash Flow Overview

Unit: Dollar
Positive Cash Flow Breakdown
    • Net proceeds from common stock o...
    • Stock-based compensation expense
    • Amortization of in-process resea...
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • License fee payments
    • Accounts receivable, net of allo...
    • Others

Cash Flow
2025-12-31
2025-09-30
2025-06-30
Net loss
-9,393,889 -8,743,646 -30,996,623
Amortization of operating lease right-of-use asset
-62,038 152,212
Stock-based compensation expense
4,280,227 2,889,762 7,946,529
Issuance of common stock for services
107,510 26,600 0
Issuance of common stock warrant
68,597 --
Amortization of in-process research and development
573,438 --
Depreciation
--0
Amortization (accretion) of operating lease right-of-use asset
-16,483 --
Deferred income tax expense
264,240 264,240 792,720
Accounts receivable, net of allowances
4,049,111 --
Inventory
352,649 3,709,006 8,940,201
Prepaid expenses
2,139,797 1,451,034 -1,386,824
Accounts payable
-2,672,280 3,599,650 5,166,831
Accrued expenses
503,054 -4,333,422 8,506,648
Accrued compensation
-198,052 -417,594 1,481,023
Operating lease liability
16,373 -68,378 -167,911
Net cash used in operating activities
-13,008,822 -11,880,790 -14,671,948
License fee payments
4,400,000 5,750,000 -
Net cash used in investing activities
-4,400,000 -5,750,000 -
Proceeds from note payable and advance from employee
-0 1,300,000
Proceeds from sale of series a preferred stock
--100
Repayment of advance from employee
-0 300,000
Net proceeds from common stock offerings
20,877,925 15,793,954 16,509,194
Redemption of series a preferred stock
--100
Net cash provided by financing activities
20,877,925 15,793,954 17,509,194
Net change in cash and cash equivalents
3,469,103 -1,836,836 2,837,246
Cash and cash equivalents at beginning of period
4,252,290 3,251,880 -
Cash and cash equivalents at end of period
7,721,393 4,252,290 -
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Net proceeds fromcommon stock offerings$20,877,925 Net cash provided byfinancing activities$20,877,925 Net change in cashand cash...$3,469,103 Canceled cashflow$17,408,822 Stock-based compensationexpense$4,280,227 Amortization of in-processresearch and development$573,438 Accrued expenses$503,054 Deferred income taxexpense$264,240 Issuance of common stockfor services$107,510 Issuance of common stockwarrant$68,597 Operating lease liability$16,373 Net cash used inoperating activities-$13,008,822 Net cash used ininvesting activities-$4,400,000 Canceled cashflow$5,813,439 Net loss-$9,393,889 Accounts receivable, netof allowances$4,049,111 License fee payments$4,400,000 Accounts payable-$2,672,280 Prepaid expenses$2,139,797 Inventory$352,649 Accrued compensation-$198,052 Amortization (accretion) ofoperating lease...-$16,483

Citius Pharmaceuticals, Inc. (CTXR)

Citius Pharmaceuticals, Inc. (CTXR)